COVID-19 vaccine

AHF Slams J&J’s Vaccine Hostage Tactics in South Africa

Retrieved on: 
Thursday, September 7, 2023
COVID-19, Infectious Diseases, Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, AIDS, Health, Pharmaceutical, General Health, Vaccine, Global North and Global South, AHF, Health policy, HIV, Associated Press, Multimedia, Hoarding, J&J, Bullying, NGO, COVID-19 vaccine, AIDS Healthcare Foundation, Serum Institute of India, European, VOW, Johnson & Johnson, Pfizer, Pharmaceutical industry, EU, Policy

According to a Health Policy Watch story , Johnson & Johnson (J&J) used scarcity during the COVID-19 pandemic as leverage to charge South Africa inflated prices on vaccine doses – a tactic that the AIDS Healthcare Foundation (AHF) has decried as ruthless pharma profiteering.

Key Points: 
  • According to a Health Policy Watch story , Johnson & Johnson (J&J) used scarcity during the COVID-19 pandemic as leverage to charge South Africa inflated prices on vaccine doses – a tactic that the AIDS Healthcare Foundation (AHF) has decried as ruthless pharma profiteering.
  • Advocates charged J&J with refusing to expand global production of its vaccine by withholding patents and manufacturing know-how from other producers and for exporting vaccines produced in South Africa to Europe while 94% of people in Africa remain unvaccinated due to severe vaccine shortages.
  • On the continent with virtually no vaccines at the time and aggressive vaccine hoarding by the Global North, South Africa had no choice but to agree to whatever J&J demanded.
  • “The situation in South Africa is the clearest indication yet of why we need a strong Global Public Health Convention based on transparency, accountability, and cooperation.

Innovators Behind the Covid Vaccines & Antivirals, HIV Treatments, and More to Be Honored at the White House, Receive Bayh-Dole Coalition American Innovator Award

Retrieved on: 
Wednesday, September 13, 2023
Columbia University, Emory University, Emtricitabine, White House, Legislation, University, University of California, Berkeley, Worcester Polytechnic Institute, Bayh–Dole Act, Interview, HIV, COVID-19 vaccine, University of Pennsylvania, Emory, Messenger, White, American Innovations, COVID-19, UC, Nobel, Pfizer, Vaccine, Pharmaceutical industry

"By bringing groundbreaking discoveries from the lab into the real world, these visionaries improved millions of lives around the globe," said Brian O'Shaughnessy, the Bayh-Dole Coalition's board chair. "None of these stories would have been possible without the 1980 Bayh-Dole Act, one of our nation's most inspired -- and most successful -- pieces of legislation."

Key Points: 
  • They will be honored at the White House while in Washington.
  • "We're thrilled to welcome some of America's greatest scientists, researchers, and entrepreneurs to our nation's capital to recognize their brilliant achievements," said Joseph P. Allen, executive director of the Bayh-Dole Coalition.
  • To access the Faces of American Innovation report and learn more about the award recipients and their pioneering work, please visit www.bayhdolecoalition.org/FacesOfAmericanInnovation2023 .
  • If you'd like to schedule an interview with any of the awardees, please contact Jack Dunn at [email protected] .

Global Chromatography Market Expected to Reach USD 10.5 Billion in 2023 with 5.5% CAGR Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Other Science, Science, Bio-Rad Laboratories, Partnership, Food, Pyrosequencing, Waters, Waters Corporation, Biotechnology, COVID-19, Chromatography, Thermo Fisher Scientific, Type, USD, Compound annual growth rate, PerkinElmer, Name, COVID-19 vaccine, Acquisition, Patent, Laboratory, Sartorius, Agilent Technologies, Medicine, Drug discovery, Growth, Applied science, Valmet, Pall Corporation, HPLC, Automation, Fine chemical, Retail, Vaccine

The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.

Key Points: 
  • The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.
  • Encompassing the chromatography instrumentation market, including liquid chromatography systems, gas chromatography systems, gel permeation chromatography, and more, along with the chromatography consumables market, this industry is poised to achieve a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
  • These include liquid chromatography systems, gas chromatography systems, gel permeation chromatography, supercritical fluid chromatography, and a range of chromatography consumables like chromatography resins and columns.
  • Market Analysis: The global chromatography market is estimated to reach USD 10.5 billion in 2023, with a projected CAGR of 5.5%.

’Negative Evidence’ for Neurological Complications of COVID Vaccines Explored in Journal of American Physicians and Surgeons (AAPS)

Retrieved on: 
Tuesday, September 5, 2023
Vaccine, Molecular mimicry, Vaccination, Cranial nerves, Physician, AAPS, Spinal cord, COVID-19, Brain, Research, COVID, Sympathetic nervous system, Messenger, Paralysis, Association of American Physicians and Surgeons, COVID-19 vaccine, Journal, Allergy, Nervous system, Diagnosis, Neurotoxicity, Injury, Pharmaceutical industry, Surgeon

TUCSON, Ariz., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The occurrence of neurological adverse events following COVID vaccines is generally acknowledged, but their significance is downplayed, writes Jane Orient , M.D., in the fall issue of the Journal of American Physicians and Surgeons.

Key Points: 
  • TUCSON, Ariz., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The occurrence of neurological adverse events following COVID vaccines is generally acknowledged, but their significance is downplayed, writes Jane Orient , M.D., in the fall issue of the Journal of American Physicians and Surgeons.
  • The devastating complications such as paralysis that are accepted as known side effects of vaccines are said to be exceedingly rare.
  • Between 2020 and 2023, 73 review papers were published describing sizable case-series of neurological complications of COVID-19 vaccines, but only three articles containing original research examining potential mechanisms.
  • “The highly publicized and coercive ‘lifesaving measures’ now look like a ticking time bomb.”
    The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Walgreens Boots Alliance Announces Leadership Transition

Retrieved on: 
Friday, September 1, 2023
Discount, Variety, Specialty, Convenience Store, Other Health, Health, Cosmetics, Pharmaceutical, General Health, Retail, Vaccine, Lead, Walgreens Boots Alliance, University, Diabetes, Pharmacy, Harvard University, Culture, COVID-19, MBA, WBA, Eli Lilly, COVID-19 vaccine, Healthcare in the United States, Harvard Business School, Guidant, Faculty, Growth, Amylin Pharmaceuticals, Eli Lilly and Company, Office of the President, Stefano Pessina, Cardiology, EPS, Rosalind Brewer, Management, Walgreens

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms.

Key Points: 
  • Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms.
  • Brewer has agreed to continue to advise WBA while the Company conducts a search for a permanent CEO.
  • Roz navigated the Company through the global pandemic, overseeing the critical rollout of vaccines in Walgreens pharmacies and to high-risk populations across the country.
  • Brewer said, “I am grateful to have had the opportunity to lead Walgreens Boots Alliance and to work alongside such talented and dedicated colleagues.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, BioNTech, Omicron, Civil service commission, Vaccination, Anaphylaxis, COVID-19, Chills, European Medicines Agency data breach, PFE, European Directive on Traditional Herbal Medicinal Products, Pfizer–BioNTech COVID-19 vaccine, Arthralgia, Messenger, European Commission, Committee, EMA, COVID-19 vaccine, Myalgia, Risk, XBB, European, MA, USE, BNTX, United Kingdom, European Medicines Agency, Committee for Medicinal Products for Human Use, Ageing, Immunodeficiency, FDA, Headache, EC, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, NYSE, Food, Fatigue, CHMP, Pharmaceutical industry, Medical device, EU, SARS-CoV-2, Pfizer

“Omicron XBB-related sublineages are antigenically distant from prior Omicron strains and continue to account for the vast majority of COVID-19 cases globally.

Key Points: 
  • “Omicron XBB-related sublineages are antigenically distant from prior Omicron strains and continue to account for the vast majority of COVID-19 cases globally.
  • Pfizer and BioNTech have also filed an application with the U.S. Food and Drug Administration (FDA) requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.
  • The COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies.
  • As with any vaccine, vaccination with COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may not protect all vaccine recipients.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

Retrieved on: 
Wednesday, August 30, 2023
COVID-19, Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, EUA, BioNTech, SARS-CoV-2, Vaccine, Heart, Inc., Omicron, Vaccination, Face, European Medicines Agency data breach, PFE, European Directive on Traditional Herbal Medicinal Products, Coronavirus, Multimedia, Inflammation, Messenger, European Commission, Rash, Committee, EMA, Seek, COVID-19 vaccine, Emergency Use Authorization, Allergy, Dizziness, Risk, Originality, XBB, European, Adolescence, BNTX, Pounding, United Kingdom, European Medicines Agency, Committee for Medicinal Products for Human Use, Ageing, EC, Regulation of tobacco by the U.S. Food and Drug Administration, Pfizer–BioNTech COVID-19 vaccine, Safety, NYSE, FD, Food, CHMP, Pericarditis, Pharmaceutical industry, EU, Bivalent, Pfizer

View the full release here: https://www.businesswire.com/news/home/20230829323192/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230829323192/en/
    The European Commission (EC) will review the CHMP’s recommendation and is expected to make a final decision soon.
  • Following a decision from the EC, the updated vaccine will be ready to ship to applicable EU member states immediately.
  • “Omicron XBB-related sublineages are antigenically distant from prior Omicron strains and continue to account for the vast majority of COVID-19 cases globally.
  • Further, the application included pre-clinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates a substantially improved response against multiple XBB sublineages, including XBB.1.5, XBB.1.16, and XBB.2.3, compared to the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

"Faces of American Innovation" Report Celebrates People Behind Life-Changing Inventions Fostered by the Bayh-Dole Act

Retrieved on: 
Wednesday, August 16, 2023
Columbia University, Emory University, Emtricitabine, University, University of California, Berkeley, Bayh–Dole Act, Worcester Polytechnic Institute, HIV, COVID-19 vaccine, Politics, University of Pennsylvania, Research, Messenger, Congress, American Innovation dollars, COVID-19, UC, Nobel, Ecosystem, Pfizer, Lithium, Pharmaceutical industry

It passed with overwhelming support from both political parties and helped catalyze decades of American innovation," said Joseph P. Allen, executive director of the Bayh-Dole Coalition.

Key Points: 
  • It passed with overwhelming support from both political parties and helped catalyze decades of American innovation," said Joseph P. Allen, executive director of the Bayh-Dole Coalition.
  • "This report celebrates the often-overlooked sacrifice and perseverance that characterizes American innovation and is required to move breakthroughs out of the lab and into the real world."
  • Birch Bayh (D-IN) and Robert Dole (R-KS) – and all the other lawmakers who helped shepherd the Bayh-Dole Act through Congress.
  • To access this year's Faces of American Innovation report and learn more about the award recipients and their pioneering work, please visit www.bayhdolecoalition.org/FacesofAmericanInnovation2023 .